Related Experiment Video
Updated: Sep 20, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Primary systemic therapy (PST) of locally advanced breast cancer using Doxorubicin/Docetaxel combination
M Dank1, E Zergenyi, Z S Domotori
1Department of Diagnostic, Radiology and Oncotherapy, Semmelweis University, Ulloi ut 78a, 1082 Budapest, Hungary. dank@radi.sote.hu
Background:
PST of locally advanced breast carcinomas causes tumour shrinkage and down-staging, therefore, optimal circumstances for surgery.
Patients And Methods:
We treated 25 stage IIIA-IIIB breast cancer patients with PST (Doxorubicin/Docetaxel). Histological diagnosis (core biopsy) was available in each case. Tumour regression and cardiac function were recorded regularly.
Results:
Five patients showed complete pathological remission. Instead of 19 mastectomies, only nine were performed and 16 patients underwent breast-conserving therapy.
Conclusion:
Using PST breast conservation rate is improved.
